Compare 3M Company (MMM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs GeneDx Holdings Corp — how do they compare? 3M Company trades at $162.47 (market cap $84.36B), while GeneDx Holdings Corp trades at $69.47 (market cap $2.02B). The key difference: 3M Company is far larger — about 41.8× GeneDx Holdings Corp's market cap, and 3M Company pays a 1.91% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and GeneDx Holdings Corp for 19 Days on average.
| MMM | WGS | |
|---|---|---|
Market Cap | $84.36B | $2.02B |
Volume | 2,325,301 | 734,640 |
Sector | Industrials | Health |
52-Week High | $183.79 | $167.51 |
52-Week Low | $141.10 | $34.51 |
Typical Hold Time | 169 Days | 19 Days |
Enterprise Value | $93.58B | $2.05B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $162.12, down 0.93% on the day, with a bearish technical signal and support near $158. The company reported strong Q2 2026 earnings, beating estimates with 5.4% organic growth and a 24.9% adjusted operating margin. Revenue for 2025 was $24.95B with net income of $3.25B, though margins have compressed from prior years. Analysts are mixed with a consensus price target of $191, representing potential upside, but high debt and weak consumer sales pose challenges.
The outlook for MMM is cautiously optimistic amid a genuine turnaround narrative. Investment opportunities include continued operational execution, shareholder returns via dividends and buybacks, and growth in industrial and electronics segments. Key risks involve persistent consumer segment weakness, litigation overhang from PFAS, and macroeconomic pressures affecting demand. The stock's valuation remains elevated with a P/E of 29.06, requiring sustained earnings growth to justify further gains.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
